| Alzheimer Disease |
1 |
1 |
| Food and Drug Administration (FDA) |
0 |
0.95 |
| Aducanumab |
0 |
0.95 |
| Social Determinants of Health |
0 |
0.45 |
| Medicare |
0 |
0.38 |
| Health Care Quality, Access, and Evaluation |
0 |
0.32 |
| Patient Safety |
0 |
0.15 |
| Care and Maintenance of Vision |
0 |
0.09 |
| Cataract |
0 |
0.09 |
| Muscular Dystrophy |
0 |
0.09 |
| Positron Emission Tomography (PET) |
0 |
0.09 |
| A-Scan Biometry |
0 |
0.06 |
| Adverse Effects |
0 |
0.06 |
| California |
0 |
0.06 |
| Cancer |
0 |
0.06 |
| Central Nervous System |
0 |
0.06 |
| Dorsum |
0 |
0.06 |
| Drug Costs |
0 |
0.06 |
| Emesis |
0 |
0.06 |
| New York |
0 |
0.06 |
| Orbit |
0 |
0.06 |
| Scan |
0 |
0.06 |
| Washington |
0 |
0.06 |